REPH - Recro Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
9.69
+0.12 (+1.25%)
As of 12:25PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close9.57
Open9.57
Bid9.57 x 300
Ask9.60 x 200
Day's Range9.50 - 9.73
52 Week Range5.81 - 10.59
Volume78,647
Avg. Volume112,501
Market Cap185.311M
Beta-1.09
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.67
Trade prices are not sourced from all markets
  • GlobeNewswire25 days ago

    Recro Pharma Secures $100 Million Credit Facility

    Proceeds Provide Funding for IV Meloxicam 30 mg Approval Milestone. Interest-only Structure Allows for Reinvestment of CDMO Cash Flows in Value Accretive Commercial Activities. Substantial Reduction in ...

  • Associated Presslast month

    Recro Pharma reports 3Q loss

    On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 48 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswirelast month

    Recro Pharma Reports Third Quarter 2017 Financial Results

    NDA Submission for IV Meloxicam Accepted by U.S. FDA for Review; PDUFA Date Set for May 26, 2018. Strong Gainesville Manufacturing Performance; Third Quarter 2017 Revenues of $17.1 Million.

  • GlobeNewswirelast month

    Recro Pharma to Present at Upcoming Investor Conferences

    MALVERN, Pa., Nov. 08, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that Gerri Henwood, ...

  • GlobeNewswirelast month

    Recro Pharma Reports Inducement Grants for New Staff

    MALVERN, Pa., Oct. 31, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced the expansion ...

  • GlobeNewswire2 months ago

    Recro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting

    IV Meloxicam 30 mg Demonstrates Statistically Significant Reductions in Pain, Along with Reductions in Opioid Rescue Use and Improvements in Several Other Pain Relief Metrics. Selected as a“ Top 6” Poster ...

  • Capital Cube2 months ago

    ETFs with exposure to Recro Pharma, Inc. : October 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Recro Pharma, Inc. Here are 5 ETFs with the largest exposure to REPH-US. Comparing the performance and risk of Recro Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
    Capital Cube2 months ago

    Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis Recro Pharma, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 16.93 million, Net Earnings of USD -8.86 million. Gross margins narrowed from 41.01% to 34.49% compared to the same period last year, operating (EBITDA) margins now -33.55% from -12.22%. Change in operating ... Read more (Read more...)

  • GlobeNewswire2 months ago

    Recro Pharma to Participate in Upcoming Investor Conferences

    MALVERN, Pa., Oct. 05, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that Gerri Henwood, ...

  • GlobeNewswire2 months ago

    Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg

    MALVERN, Pa., Oct. 05, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that the U.S. ...

  • GlobeNewswire3 months ago

    Recro Pharma Reports Inducement Grants for New Staff

    MALVERN, Pa., Sept. 29, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced the expansion ...

  • GlobeNewswire3 months ago

    Recro Pharma Announces FDA Acceptance for Review of New Drug Application for IV Meloxicam 30mg

    MALVERN, Pa., Sept. 28, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that the U.S. ...

  • Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars
    Zacks4 months ago

    Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars

    Adamas Pharmaceuticals' (ADMS) Gocovri was approved by the FDA for treating dyskinesia in patients with Parkinson's disease. This led to an upside in shares.

  • Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View
    Zacks4 months ago

    Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View

    Lannett (LCI) reported in-line Q4 earnings and sales. The FDA approved multiple pending ANDAs during the quarter. Also, the company provided strong outlook for 2018.

  • Associated Press4 months ago

    Recro Pharma reports 2Q loss

    On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 48 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Capital Cube6 months ago

    ETFs with exposure to Recro Pharma, Inc. : June 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Recro Pharma, Inc. Here are 5 ETFs with the largest exposure to REPH-US. Comparing the performance and risk of Recro Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)